Topical calcineurin inhibitors in dermatology;Topische calcineurin-inhibitoren in der dermatologie

Pharmazie in Unserer Zeit

Volumn 34, Issue 4, 2005, Pages 314-320

  Hengge, Ulrich ^a   Ruzicka, Thomas ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIPRURITIC AGENT; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DOUGLAN; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; TACROLIMUS; UNCLASSIFIED DRUG;

ATOPIC DERMATITIS; CARCINOGENICITY; CORTICOSTEROID THERAPY; DERMATOLOGY; GERMANY; HUMAN; REVIEW; RISK FACTOR; SKIN DISEASE; SYMPTOMATOLOGY;

EID: 22244431914     PISSN: 00483664     EISSN: None     Source Type: Journal    
DOI: 10.1002/pauz.200500131     Document Type: Review

References (22)

1. Williams, H., Robertson, C., Stewart, A., Ait-Khaled, N., Anabwani, G., Anderson, R., Asher, I., Beasley, R., Bjorksten, B., Burr, M., Clayton, T., Crane, J., Ellwood, P., Keil, U., Lai, C., Mallol, J., Martinez, F., Mitchell, E., Montefort, S., Pearce, N., Shah, J., Sibbald, B., Strachan, D., von Mutius, E., Weiland, S.K.: Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J. Allergy Clin. Immunol. 103 (1999), 125-138.
2. Herd, R.M.: The morbidity and costs of atopic dermatitis. In: Atopic dermatitis. The epidemiology, causes and prevention of atopic eczema. Williams, H.C. (ed.), Cambridge, Cambridge University Press, 2000, pp 85-95.
3. Eichenfield, L.F., Hanifin, J.M., Beck, L.A., Lemanske, R.F. Jr, Sampson, H.A., Weiss, S.T., Leung, D.Y.: Atopic dermatitis and asthma: parallels in the evolution of treatment. Pediatrics 111 (2003), 608-616.
4. Alomar, A., Berth-Jones, J., Bos, J.D., Giannetti, A., Reitamo, S., Ruzicka, T., Stalder, J.F., Thestrup-Pedersen, K.; European Working Group on Atopic Dermatitis: The role of topical calcineurin inhibitors in atopic dermatitis. Br. J. Dermatol. 151 Suppl 70 (2004), 3-27.
5. Ashcroft, D.M., Dimmock, P., Garside, R., Stein, K., Williams, H.C.: Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. Br. Med. J. 330 (2005), 516.
6. De Paulis, A., Stellato, C., Cirillo, R., Ciccarelli, A., Oriente, A., Marone, G.: Anti-inflammatory effect of FK-506 on human skin mast cells. J. Invest. Dermatol. 99 (1992), 723-728.
7. Hom, J.T., Estridge, T.: FK506 and rapamycin modulate the functional activities of human peripheral blood eosinophils. Clin. Immunol. Immunopathol. 68 (1993), 293-300.
8. Panhans-Gross, A., Novak, N., Kraft, S., Bieber, T.: Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J. Allergy Clin. Immunol. 107 (2001), 345-352.
9. Wollenberg, A., Sharma, S., von Bubnoff, D., Geiger, E., Haberstok, J., Bieber, T.: Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J. Allergy Clin. Immunol. 107 (2001), 519-525.
10. Meingassner, J.G., Kowalsky, E., Schwendinger, H., Elbe-Burger, A., Stutz, A.: Pimecrolimus does not affect Langerhans cells in murine epidermis. Br. J. Dermatol. 149 (2003), 853-857.
11. Fleischer, A.B. Jr, Ling, M., Eichenfield, L., Satoi, Y., Jaracz, E., Rico, M.J., Maher, R.M., Tacrolimus Ointment Study Group: Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J. Am. Acad. Dermatol. 47 (2002), 562-570.
12. Pournaras, C.C., Lubbe, J., Saurat, J.H.: Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (Fk506). J. Invest. Dermatol. 116 (2001), 480-481.
13. Remitz, A., Kyllonen, H., Granlund, H., Reitamo, S.: Tacrolimus ointment reduces Staphylococcal colonization of atopic dermatitis lesions. J. Allergy Clin. Immunol. 107 (2001), 196-197.
14. Paller, A., Eichenfield, L.F., Leung, D.Y., Stewart, D., Appell, M.: A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J. Am. Acad. Dermatol. 44 (2001), S47-S57.
15. Wahn, U., Bos, J.D., Goodfield, M., Caputo, R., Papp, K., Manjra, A., Dobozy, A., Paul, C. Molloy, S., Hultsch, T., Graeber, M., Cherill, R., de Prost, Y., Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 110 (2002), e2.
16. Ruzicka, T., Bieber, T., Schopf, E., Rubins, A., Dobozy, A., Bos, J.D., Jablonska, S., Ahmed, I., Thestrup-Pedersen, K., Daniel, F., Finzi, A., Reitamo, S.: A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N. Engl. J. Med. 337 (1997), 816-821.
17. Van Leent, E.J.M., De Vries, H., Scott, G., et al.: Low blood concentrations of pimecrolimus (Elidel, SDZ ASM-981) after topical treatment of adultes with atopic eczema. J. Eur. Acad. Dermatol. Venereol. 15 (2001), P2-8 (Abstract).
18. Reitamo, S., Wollenberg, A., Schopf, E., Perrot, J.L., Marks, R., Ruzicka, T., Christophers, E., Kapp, A., Lahfa, M., Rubins, A., Jablonska, S., Rustin, M.: Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch. Dermatol. 136 (2000), 999-1006.
19. Rico, M.J., Naylor, M., Elmets, C.A., et al.: Treatment with Tacrolimus ointment is not associated with an increase in non-melaoma skin cancer. J. Eur. Acad. Dermatol. Venereol. 16 (2002), P2-49 (Abstract).
20. Frieling, U.M., Schaumberg, D.A., Kupper, T.S., Muntwyler, J., Hennekens, C.H.: A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the physician's health study. Arch. Dermatol. 136 (2000), 179-184.
21. Ellis, C.N., Drake, L.A., Prendergast, M.M., Abramovits, W., Boguniewicz, M., Daniel, C.R., Lebwohl, M., Palier, A.S., Stevens, S.R., Whitaker-Worth, D.L., long, K.B.: Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J. Am. Acad. Dermatol. 48 (2003), 553-563.
22. Abramovits, W., Boguniewicz, M., Prendergast, M.M., Tokar, M., long, K.B.: Comparisons of efficacy and cost-effectiveness of topical immunomodulators in the management of atopic dermatitis. J. Med. Economics 6 (2003), 1-14.